在绵羊和山羊中对甲尼达的比较药理动力学评估
Charbel Fadel1, Beata Łebkowska-Wieruszewska2, Firas Serih3
1Department of Veterinary Sciences, University of Pisa, Viale delle Piagge, 2, 56124 Pisa, Italy; Department of Veterinary Medicine, Lebanese University, Faculty of Agronomy Bldg., University Street, Dekwaneh, Beirut, Lebanon.
Research in veterinary science
|January 1, 2025
概括
羊和山羊中的甲尼达的药理动力学显示出迅速的排泄,山羊的排泄速度更快. 为了在小反动物中有效的抗菌和抗原动物治疗,需要对特定物种进行剂量调整.
科学领域:
- 兽医药理学 兽医药理学
- 药物新陈代谢 药物新陈代谢
- 药理动力学 药理动力学
背景情况:
- 甲尼达 (MTZ) 是一种5 - 尼特罗伊米达,具有抗菌和抗原动物的特性.
- 由于缺乏药理动力学数据,其在农场动物中的使用是有限的.
- 了解MTZ的药理动力学对于其在绵羊和山羊中的潜在应用至关重要.
研究的目的:
- 为了确定羊和山羊中甲化 (MTZ) 的药理动力学.
- 为了比较静脉注射 (IV) 和皮下注射 (SC) 后的MTZ药理动力学.
- 提供数据,以建立适合小反动物的剂量方案.
主要方法:
- 一个两相,单剂量,交叉研究设计用于绵羊 (n=5) 和山羊 (n=5).
- 甲二醇 (2毫克/公斤) 通过IV和SC途径用一周的洗期给药.
- 使用高性能液体染色学 (HPLC) 在24小时内量化血药物度.
主要成果:
- 甲尼达在两种物种中均表现出快速清除,在山羊中清除速度明显更快.
- 与绵羊相比,山羊的清除率更高,曲线下的面积 (AUC) 值更低.
- 在两种物种中,IV和SC路线的生物利用率相对较高.
结论:
- 绵羊和山羊之间存在特定物种的药理动力学差异,需要对甲尼达的剂量进行调整.
- 皮下注射显示了作为小反动物中美特罗尼达的实用途径的潜力.
- 需要进一步的研究,包括多次剂量研究,以确定在患病的绵羊和山羊中使用美特罗尼达的最佳治疗方案.
相关概念视频
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
80
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
80
Bioequivalence: Overview
918
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
918
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
173
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
173
Nonlinear Pharmacokinetics: Overview
264
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
264
One-Compartment Open Model: Wagner-Nelson and Loo Riegelman Method for ka Estimation
382
This lesson introduces two critical methods in pharmacokinetics, the Wagner-Nelson and Loo-Riegelman methods, used for estimating the absorption rate constant (ka) for drugs administered via non-intravenous routes. The Wagner-Nelson method relates ka to the plasma concentration derived from the slope of a semilog percent unabsorbed time plot. However, it is limited to drugs with one-compartment kinetics and can be impacted by factors like gastrointestinal motility or enzymatic degradation.
On...
On...
382
Factors Influencing Drug Absorption: Presystemic Elimination
176
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
176


